JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemstapat, K.
Right arrow Articles by Smith, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemstapat, K.
Right arrow Articles by Smith, M. T.
Related Collections
Right arrow Mechanisms
Right arrow Pain
Right arrow Pharmacology

Anesth Analg 2003;97:494-505
© 2003 International Anesthesia Research Society


PAIN MEDICINE

Morphine-3-Glucuronide’s Neuro-Excitatory Effects Are Mediated via Indirect Activation of N-Methyl-D-Aspartic Acid Receptors: Mechanistic Studies in Embryonic Cultured Hippocampal Neurones

Kamondanai Hemstapat, BPharm, Gregory R. Monteith, PhD, Deborah Smith, BPharm (Hons), and Maree T. Smith, PhD

School of Pharmacy, The University of Queensland, St Lucia Campus, Brisbane, Australia

Address correspondence and reprint requests to Maree T. Smith, PhD, School of Pharmacy, The University of Queensland, St Lucia, Brisbane, Queensland 4072, Australia. Address e-mail to m.smith{at}pharmacy.uq.edu.au

Indirect evidence indicates that morphine-3-glucuronide (M3G) may contribute significantly to the neuro-excitatory side effects (myoclonus and allodynia) of large-dose systemic morphine. To gain insight into the mechanism underlying M3G’s excitatory behaviors, we used fluo-3 fluorescence digital imaging techniques to assess the acute effects of M3G (5–500 µM) on the cytosolic calcium concentration ([Ca2+]CYT) in cultured embryonic hippocampal neurones. Acute (3 min) exposure of neurones to M3G evoked [Ca2+]CYT transients that were typically either (a) transient oscillatory responses characterized by a rapid increase in [Ca2+]CYT oscillation amplitude that was sustained for at least ~30 s or (b) a sustained increase in [Ca2+]CYT that slowly recovered to baseline. Naloxone-pretreatment decreased the proportion of M3G-responsive neurones by 10%–25%, implicating a predominantly non-opioidergic mechanism. Although the naloxone-insensitive M3G-induced increases in [Ca2+]CYT were completely blocked by N-methyl-D-aspartic acid (NMDA) antagonists and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate antagonist), CNQX did not block the large increase in [Ca2+]CYT evoked by NMDA (as expected), confirming that M3G indirectly activates the NMDA receptor. Additionally, tetrodotoxin (Na+ channel blocker), baclofen ({gamma}-aminobutyric acidB agonist), MVIIC (P/Q-type calcium channel blocker), and nifedipine (L-type calcium channel blocker) all abolished M3G-induced increases in [Ca2+]CYT, suggesting that M3G may produce its neuro-excitatory effects by modulating neurotransmitter release. However, additional characterization is required.

IMPLICATIONS: Large systemic doses of morphine administered to some patients for cancer pain management have been reported to produce myoclonus and allodynia. Indirect evidence implicates the major morphine metabolite, morphine-3-glucuronide (M3G), in these neuro-excitatory side effects. Hence, this study was designed to gain insight into the cellular mechanism responsible for M3G’s neuro-excitatory actions.




This article has been cited by other articles:


Home page
JCOHome page
M. P. Davis and M. Angst
In Reply
J. Clin. Oncol., March 20, 2008; 26(9): 1565 - 1565.
[Full Text] [PDF]


Home page
Anesth. Analg.Home page
E. Saboory, M. Derchansky, M. Ismaili, S. S. Jahromi, R. Brull, P. L. Carlen, and H. El Beheiry
Mechanisms of Morphine Enhancement of Spontaneous Seizure Activity
Anesth. Analg., December 1, 2007; 105(6): 1729 - 1735.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
C. W. Vaughan and M. Connor
In Search of a Role for the Morphine Metabolite Morphine-3-Glucuronide
Anesth. Analg., August 1, 2003; 97(2): 311 - 312.
[Full Text] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2003 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2003 by the International Anesthesia Research Society.